← 返回前沿论文

系统性免疫抑制限制了 NK 细胞疗法在胰腺癌中的疗效

英文原题:Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer.

PubMed 2026/07/08(内容时间) Mol Cancer Q1 · IF 42.2(JCR 2025)

研究概要

自然杀伤(NK)细胞在癌症免疫监视中发挥关键作用,并被认为是包括胰腺导管腺癌(PDAC)在内的多种癌症的有效免疫治疗工具。

中文摘要

自然杀伤(NK)细胞在癌症免疫监视中发挥关键作用,并被认为是包括胰腺导管腺癌(PDAC)在内的多种癌症的有效免疫治疗工具。越来越多的证据表明,癌症发生伴随全身性免疫扰动。然而,PDAC肿瘤负荷对全身NK细胞的影响仍知之甚少。PDAC荷瘤小鼠脾脏中NK细胞频率降低且功能失调。我们在脾脏中发现Gr-1+髓系细胞增多,其对内源性和过继转移的NK细胞频率和功能均产生负面影响。载脂蛋白E(ApoE)是一种脂质代谢调节因子,在荷瘤小鼠的Gr-1+髓系细胞中上调,促进脂质氧化和活性氧(ROS)生成。在Gr-1+髓系细胞中基因敲除Apoe可消除其对NK细胞功能的抑制作用。此外,脂质代谢抑制剂治疗可恢复脾脏和肿瘤微环境中内源性和过继转移NK细胞的效应功能。这些研究强调了在应用基于NK细胞的免疫疗法之前,了解PDAC患者预先存在的全身性改变的重要性。

展开英文摘要原文

Nature killer (NK) cell plays a critical role in cancer immunosurveillance and is considered a potent immunotherapeutic tool for many cancers, including pancreatic ductal adenocarcinomas (PDACs). Increasing evidence suggests that cancer occurs with systemic immune perturbations. However, the effects of PDAC tumor burden on systemic NK cells remain poorly understood. PDAC tumor-bearing mice display decreased frequency and dysfunction of NKs the spleens. We identified an increase in Gr-1+ myeloid cells within the spleens, which negatively impacts both endogenous and adoptively transferred NK cell frequency and function. Apolipoprotein E (ApoE), a lipid metabolism regulator, is upregulated in Gr-1+ myeloid cells of tumor-bearing mice, promoting lipid oxidation and reactive oxygen species (ROS) generation. Genetic knockout of Apoe in Gr-1+ myeloid cells abrogate their suppressive effects on NK cell function. Furthermore, treatment with lipid metabolism inhibitors restores endogenous and adoptively transferred NKs' effector function in the spleens and tumor microenvironment. These studies underscore the importance of understanding preexisting systemic alterations in PDAC patients before applying NK cell-based immunotherapies.

论文信息

作者
He C、Wang D、Hu T、Gonzalez D、Thakur R、Matysniak DP、King RJ、Kollala SS
第一作者单位
Department of Oncology Science, University of Oklahoma Health Campus, 940 Stanton L. Young Blvd., BMSB 332, Oklahoma City, OK, 73104, USA.United States
通讯作者单位
Department of Oncology Science, University of Oklahoma Health Campus, 940 Stanton L. Young Blvd., BMSB 332, Oklahoma City, OK, 73104, USA. kamiya-mehla@ouhsc.edu.United States
期刊
Molecular cancer2026 Jul 8
原文标识
PubMed 42421015 · DOI 10.1186/s12943-025-02340-8